Country share of clinical trial country-uses
STO-REC-STATMKSSJ1T3 Research
16%
United States · 2021–2023
Country share of clinical trial country-uses in United States stood at 16% in 2021–2023 (IQVIA).
- Publisher
- IQVIA
- Authority tier
- T3 Research
- Locator
- Country utilization is heavily consolidated in U.S., China and Western European countries
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.
Verbatim extraction verified: The figure 16% is directly attested in the quoted passage (Country utilization is heavily consolidated in U.S., China and Western European countries).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1
- MLA
- IQVIA Institute. "Rethinking Clinical Trial Country Prioritization." 2023, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1.
- Chicago
- IQVIA Institute. "Rethinking Clinical Trial Country Prioritization." 2023. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1.
- BibTeX
- @misc{iqvia2023country5774x1, author = {{IQVIA Institute}}, title = {Rethinking Clinical Trial Country Prioritization}, year = {2023}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_MKSSJ11HJT01770TDNK75774X1}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- IQVIA Institute · homepage ↗
- Authority tier
- Tier 3 · Industry & Research
- Report
- Rethinking Clinical Trial Country Prioritization
- Type
- Press release
- Published
- —
- Locator
- Country utilization is heavily consolidated in U.S., China and Western European countries
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Archival URI
- /stat/stat_MKSSJ11HJT01770TDNK75774X1